《大行报告》大摩上调阿里健康(00241.HK)目标价至21.4元 评级「增持」
摩根士丹利发表报告指,阿里健康(00241.HK)2020财年下半财年的业绩好过该行预期,主要是受到直接制药业务及互联网医疗服务的强劲增长所带动。该行将阿里健目标价由原来的14.5元上调至21.4元,此相当预测2022年市销率的8.6倍,以反映在有利的政策下,在线药品销售及互联网医疗服务的持续增长,维持「增持」投资评级。
该行将阿里健康的2021至2023财年销售预测上调5至8%,主要是因为疫情後在线药品销售会有进一步渗透;4月20日前完成81亿元的资产注入及相应的新股发行,以及互联网医疗领域的增长加快。这意味着公司2020至2022财年的销售年复合增长率达73%,并会在2022财年达到收支平衡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.